Search

Author/Creator Daniel, Gregory

3. Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations. (January 2019)

Authors:
Richardson, Elizabeth; Burnell, Jessica; Adams, Heather R.; Bohannon, Richard W.; Bush, Elizabeth Nicole; Campbell, Michelle; Chen, Wen Hung; Coons, Stephen Joel; Papadopoulos, Elektra; Reeve, Bryce R.; Rooks, Daniel; Daniel, Gregory
Journal:
Therapeutic innovation & regulatory science
Issue:
Volume 53:Number 1(2019:Jan.)
Page Start:
146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. Issue 3 (2nd February 2018)

Authors:
Sobel, Rachel E.; Bate, Andrew; Marshall, James; Haynes, Kevin; Selvam, Nandini; Nair, Vinit; Daniel, Gregory; Brown, Jeffrey S.; Reynolds, Robert F.
Journal:
Pharmacoepidemiology and drug safety
Issue:
Volume 27:Issue 3(2018)
Page Start:
332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative. Issue 11 (13th September 2020)

Authors:
Orsini, Lucinda S.; Monz, Brigitta; Mullins, C. Daniel; Van Brunt, David; Daniel, Gregory; Eichler, Hans‐Georg; Graff, Jennifer; Guerino, John; Berger, Marc; Lederer, Nirosha M.; Jonsson, Pall; Schneeweiss, Sebastian; Wang, Shirley V.; Crown, William; Goettsch, Wim; Willke, Richard J.
Journal:
Pharmacoepidemiology and drug safety
Issue:
Volume 29:Issue 11(2020)
Page Start:
1504
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗